MADRID – Systemic corticosteroid use and BMI impact risk of serious adverse events with certolizumab.
“This study was narrow in nature and we certainly need more information on the safety of Zostavax with patients on biologics with other mechanisms...
ATLANTA – Biologic-naive patients with PsA responded better to ixekizumab than to adalimumab for skin and joint symptoms, and at least as well...
From the Journals
The monoclonal antibody ixekizumab has shown efficacy in moderate to severe psoriasis over a 4-year follow-up.
News from the FDA/CDC
Pfizer said that current plans are to launch the drug in the United States in 2023.
LAS VEGAS – Optimizing anti-TNF-alpha treatment starts with recognizing there is a loss of response over time, Dr. Kerdel said.
LAS VEGAS – Home-based UVB phototherapy is gaining in popularity and is comparable with in-office UVB in terms of accuracy and efficacy.
ATLANTA – Guselkumab, an anti-IL-23p19 monoclonal antibody, showed efficacy versus placebo for active PsA in both biologic-naive and TNFi-treated...
ATLANTA – Investigators found no confirmed varicella infection cases at 6 weeks.
Topics in this guideline for pediatric psoriasis include systemic and topical treatments, management of comorbidities, and quality of life.